Werewolf Therapeutics reported revenue of $21.00M and net income of $3.67M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 27.22M | 18.45M | 27.42M | 28.28M | 30.61M | 31.43M | 35.30M | 35.64M | 35.66M | 39.11M | 43.28M | 43.70M | 43.72M | 44.83M | 44.83M | 45.34M | 47.27M | 48.60M | 48.60M | 48.60M | ||||||
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 4.15M | 4.97M | 7.28M | 4.46M | 8.08M | 5.90M | 1.50M | 0.74M | 1.14M | 0.01M | 21.00M | |||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.79M | 13.40M | 10.95M | 13.89M | 13.07M | 15.86M | 11.71M | 9.58M | 10.84M | 9.65M | 12.91M | 15.27M | 12.53M | 15.73M | 13.12M | 13.14M | 11.63M | 6.93M | 8.18M | 6.16M | ||||||
| Selling, General & AdministrativeSG&A | 4.01M | 4.48M | 4.42M | 5.23M | 4.44M | 4.60M | 4.98M | 4.57M | 4.31M | 4.81M | 5.00M | 4.83M | 4.60M | 4.62M | 4.87M | 4.40M | 4.09M | 2.48M | 5.09M | 7.68M | ||||||
| Other Operating ExpensesOther Opex | ||||||||||||||||||||||||||
| Operating ExpensesOpex | 13.79M | 17.88M | 15.37M | 19.12M | 17.51M | 20.46M | 16.69M | 14.15M | 15.15M | 14.46M | 17.90M | 20.10M | 17.12M | 20.35M | 17.99M | 17.54M | 15.73M | 9.42M | 13.27M | 13.84M | ||||||
| Operating IncomeOp. Inc | -13.79M | -17.88M | -15.37M | -14.97M | -12.54M | -13.18M | -12.22M | -6.07M | -9.25M | -12.96M | -17.16M | -18.96M | -17.12M | -20.35M | -17.99M | -17.54M | -15.73M | -9.42M | -13.27M | 7.16M | ||||||
| EBIT | -13.79M | -17.88M | -15.37M | -14.97M | -12.54M | -13.18M | -12.22M | -6.07M | -9.25M | -12.96M | -17.16M | -18.96M | -17.12M | -20.35M | -17.99M | -17.54M | -15.73M | -9.42M | -13.27M | 7.16M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.17M | 0.95M | 1.00M | 1.01M | 1.00M | 1.14M | 1.24M | 1.27M | 1.26M | 1.30M | 1.34M | 1.37M | 1.37M | 0.47M | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.05M | -0.03M | 0.04M | 0.10M | 0.59M | 1.18M | 1.52M | 1.95M | 1.97M | 1.98M | 1.97M | 1.79M | 1.60M | 1.31M | 1.00M | 0.85M | 0.70M | 0.56M | 0.43M | 0.28M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.02M | -0.02M | 0.28M | 0.00M | 0.07M | -1.11M | -0.03M | -0.01M | -0.01M | -0.00M | 1.61M | 0.10M | -0.09M | 0.17M | 0.01M | 1.84M | 0.67M | -3.35M | ||||||||
| Non Operating IncomeNon Op. Inc. | 0.04M | 0.01M | 0.02M | 0.38M | 0.60M | 1.25M | 0.24M | 0.97M | 0.97M | 0.96M | 0.97M | 1.71M | 0.45M | -0.05M | -0.10M | -0.44M | -0.64M | 1.04M | -0.26M | -3.49M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -13.74M | -17.92M | -15.33M | -14.88M | -11.95M | -12.00M | -10.88M | -5.07M | -8.28M | -12.00M | -16.19M | -18.31M | -16.77M | -20.31M | -18.26M | -17.99M | -16.37M | -10.22M | -14.21M | 6.96M | ||||||
| Profit After TaxPAT | -13.76M | -17.87M | -15.34M | -14.59M | -11.94M | -11.93M | -11.98M | -5.10M | -8.29M | -12.00M | -16.19M | -17.25M | -16.67M | -20.40M | -18.09M | -17.98M | -16.37M | -8.38M | -13.53M | 3.67M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -13.74M | -17.92M | -15.33M | -14.88M | -11.95M | -12.00M | -10.88M | -5.07M | -8.28M | -12.00M | -16.19M | -18.31M | -16.77M | -20.31M | -18.26M | -17.99M | -16.37M | -10.22M | -14.21M | 6.96M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -13.74M | -17.92M | -15.33M | -14.88M | -11.95M | -12.00M | -10.88M | -5.07M | -8.28M | -12.00M | -16.19M | -18.31M | -16.77M | -20.31M | -18.26M | -17.99M | -16.37M | -10.22M | -14.21M | 6.96M | ||||||
| Income towards Parent CompanyParent Net Inc | -13.74M | -17.92M | -15.33M | -14.88M | -11.95M | -12.00M | -10.88M | -5.07M | -8.28M | -12.00M | -16.19M | -18.31M | -16.77M | -20.31M | -18.26M | -17.99M | -16.37M | -10.22M | -14.21M | 6.96M | ||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -13.76M | -17.87M | -15.34M | -14.59M | -11.94M | -11.93M | -10.88M | -5.07M | -8.28M | -12.00M | -16.19M | -18.31M | -16.77M | -20.31M | -18.26M | -17.99M | -16.37M | -10.22M | -14.21M | 6.96M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.51 | -0.97 | -0.56 | -0.53 | -0.40 | -0.41 | -0.31 | -0.14 | -0.23 | -0.34 | -0.39 | -0.42 | -0.38 | -0.47 | -0.41 | -0.40 | -0.36 | -0.22 | -0.29 | 0.14 | ||||||
| EPS (Diluted) | -0.51 | -0.97 | -0.56 | -0.53 | -0.40 | -0.41 | -0.31 | -0.14 | -0.23 | -0.34 | -0.39 | -0.42 | -0.38 | -0.46 | -0.41 | -0.40 | -0.36 | -0.22 | -0.29 | 0.14 | ||||||
| Shares Outstanding | 27.19M | 18.45M | 27.39M | 27.52M | 29.76M | 28.86M | 34.78M | 35.56M | 35.65M | 35.65M | 41.61M | 43.52M | 43.70M | 43.33M | 44.83M | 44.98M | 45.80M | 46.02M | 48.60M | 48.60M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 27.19M | 18.45M | 27.39M | 27.52M | 29.76M | 28.86M | 34.78M | 35.56M | 35.65M | 35.65M | 41.61M | 44.04M | 43.70M | 43.86M | 44.83M | 44.98M | 45.80M | 46.81M | 49.39M | 48.60M | ||||||
| EBITDA | -13.79M | -17.88M | -15.37M | -14.97M | -12.54M | -13.18M | -12.22M | -6.07M | -9.25M | -12.96M | -17.16M | -18.96M | -17.12M | -20.35M | -17.99M | -17.54M | -15.73M | -9.42M | -13.27M | 7.16M | ||||||
| Interest ExpensesInt Expense | 0.17M | 0.95M | 1.00M | 1.01M | 1.00M | 1.14M | 1.24M | 1.27M | 1.26M | 1.30M | 1.34M | 1.37M | 1.37M | 0.47M |